Dr Reddys Laboratories (RDY) Common Equity (2009 - 2026)

Dr Reddys Laboratories has reported Common Equity for 18 years, with the latest figure at $4.1 billion in Q2 2026.

• On a quarterly basis, Common Equity fell 1.17% year-over-year to $4.1 billion in Q2 2026; TTM through Jun 2026 was $4.1 billion, a 1.17% decrease from a year earlier, with the FY2026 full-year figure at $4.1 billion, up 2.71% from the prior year.
• Common Equity was $4.1 billion for Q2 2026 at Dr Reddys Laboratories, down from $4.2 billion in the prior quarter.
• The five-year high for Common Equity was $4.2 billion in Q4 2025, with the low at $2.5 billion in Q1 2022.
• Average Common Equity over 5 years is $3.4 billion, with a median of $3.5 billion recorded in 2024.
• The sharpest annual moves came in 2024 and 2026: Common Equity advanced 20.61% in 2024, then slipped 1.17% in 2026.
• Over 5 years, Common Equity stood at $2.7 billion in 2022, then gained by 19.9% to $3.2 billion in 2023, then increased by 18.39% to $3.8 billion in 2024, then rose by 10.79% to $4.2 billion in 2025, then dropped by 3.19% to $4.1 billion in 2026.
• The last three Common Equity figures came in at $4.1 billion (Q2 2026), $4.2 billion (Q1 2026), and $4.2 billion (Q4 2025), per Business Quant data.